Citations 2
P257 Efficacy and safety up to 3 years of risankizumab in moderately to severely active ulcerative colitis patients: COMMAND interim results
Atreya, Raja, Louis, Edouard, Loftus, Edward V, Rubin, David T, Dubinsky, Marla C., Hisamatsu, T, Kalabic, Jasmina , Méndez, Paloma, Chen, S H, Shah, Saajan, Morisset, Pierre, Duan, W Rachel, Coll, Christina, Panaccione, Remo, Atreya, Raja Narayana , Rubin, David T. , Hisamatsu, Tadakazu, Mendez, Paloma, Morisset, Pierre, Duan, W Rachel, Panaccione, Remo
E-Posters | June 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: A240.2-A241
P189 Efficacy and safety of upadacitinib maintenance treatment in patients with moderately to severely active crohn’s disease: 3-year results from U-ENDURE
Loftus, Edward V, D’Haens, Geert R, Louis, Edouard, Regueiro, Miguel D, Jairath, Vipul, Magro, Fernando, Nakase, Hiroshi, Dubcenco, Elena, Fish, Irina, Kim, Kimmie, Wang, Y , Anyanwu, Samuel I, Aponte, Fernando, Ogholikhan, Sina, Coll, Christina, Blumenstein, Irina, D’Haens, Geert R, Jairath, Vipul , Magro, F , Nakase, Hiroshi , Anyanwu, Samuel, Ogholikhan, Sina, Blumenstein, Irina
E-Posters | June 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: A198.1-A198